On May 6, 2022 The Marble Center for Cancer Nanomedicine—housed within the Koch Institute for Integrative Cancer Research at MIT—reported the launch of an affiliate program that will fuel scientific collaborations between academic and industry members and enable breakthrough innovations in all areas impacted by nanomedicine, from drug delivery to gene editing, biomedical imaging, and diagnostics (Press release, Alloy Therapeutics, MAY 6, 2022, View Source [SID1234642127]). Inaugural members of this program are Alloy Therapeutics, Danaher Corporation, FUJIFILM Holdings America Corporation, and Sanofi.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Industry Affiliate Program at the Marble Center in Nanomedicine (IAMNano) will provide its members with exclusive access to a thriving research community at the Koch Institute and flagship initiatives such as the Convergence Scholars Program, as well as create opportunities for formal scientific collaborations with member laboratories. The Marble Center will also launch an Industry Advisory Board to leverage insight and business development expertise as part as of its broader efforts to accelerate biomedical innovations toward clinical applications. Tarek Fadel, Assistant Director of the Marble Center, has spearheaded efforts to create the unique partnership model at IAMNano and will provide dedicated support to member organizations.
"We see this initiative as part of our natural evolution as a community of excellence in nanomedicine," said Koch Institute member and Marble Center Director Sangeeta N. Bhatia, the John J. and Dorothy Wilson Professor of Health Sciences and Technology and Electrical Engineering and Computer Science. "For the past six years, our priority has been to seed world-class research, catalyze scientific exchange and innovation, and invest in the development of a multifaceted research community. The design of IAMNano was guided by many discussions in and outside of MIT, including input from an external review board that helped us shape the program’s current design. We look forward to working with our new industry partners to grow the Marble Center as a hub in nanomedicine and help shape the future of the field for years to come."
Chris Pacheco, General Partner at 82VS, Alloy Therapeutics’ Venture Studio, added: "Alloy Therapeutics is committed to investing in enabling technologies that allow the best treatments to get to patients, and we recognize that breakthroughs in drug delivery technology are essential to that effort. Our Venture Studio partners with promising scientific entrepreneurs to create innovative therapeutic companies, and we are eager to support the advances from the Marble Center for Cancer Nanomedicine, already a leader in translational technologies and rising nanomedicine inventors."
"As a science and technology leader, Danaher Corporation recognizes just how important it is to invest in platform technologies that will one day be instrumental in delivering nucleic acid and cell-based therapeutics to patients. At Danaher, we enable cell and genomic medicines manufacturing, and we are committed to advancing the very best ideas—those that result in products that improve patients’ lives." said Vanessa Almendro, Head of Innovation Ecosystems at Danaher Corporation. "Collaborating with the IAMNano community furthers our ambitions to develop transformative technologies and to prepare the next generation of nanomedicine scientific leaders."
"At Fujifilm we are committed to advancing the field of life science research with the goal of supporting all stages of therapeutic development," notes Bruce E. Novich Sc.D., Division President, FUJIFILM Holdings America Corporation and member, Fujifilm Life Science Strategic Business Office, based in Cambridge, Mass. "We firmly believe that the only way to advance progress in this field is to collaborate with other leaders in the industry and academia. IAMNano presents us with the environment to share research developments to bring new and life-changing innovative treatments to patients faster."
Christian Mueller, Global Head of Genomic Medicine Unit, at Sanofi, commented: "Sanofi’s participation in the Marble Center for Cancer Nanomedicine supports our mission to develop innovative cell and gene therapies. Through this program we envision creating strong partnerships and collaborations with the Marble Center research community and other affiliate members that will accelerate the research and development of nanomedicine approaches across a broad range of diseases."